

Paper # 41
Attachment

FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Attorney Docket No.: 11823-002630US	Application No.: 08/484,537
		Applicant: QUEEN ET AL.	
		Filing Date: June 7, 1995	Group: 1642

Reference Designation **U.S. PATENT DOCUMENTS** **Page 1 of 2**

Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)

FOREIGN PATENT DOCUMENTS

	Document No.	Date	Country	Class	Sub-class	Translation (Yes/No)

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AB	Opposition to EP 0456216, Third Party Observations, May 25, 1998.
AB	Opposition to EP 0456216, Further Submissions of Medical Research Council, June 24, 1998.
AC	Opposition to EP 0456216, Summons to Attend Oral Proceedings, May 12, 1999.
AD	Opposition to EP 0456216, Further Submissions of Protein Design Labs, Inc., September 17, 1999.
AE	Opposition to EP 0456216, Further Submissions of Protein Design Labs, Inc., October 26, 1999.
AF	Opposition to EP 0456216, Further Submissions of Protein Design Labs, Inc., December 1, 1999.
AG	Opposition to EP 0456216, Further Third Party Observations, December 14, 1999.
AH	Opposition to EP 0456216, Further Submissions of Celltech Therapeutics, December 16, 1999.
AI	Opposition to EP 0456216, Attachment to Celltech Therapeutics' submissions of December 16, 1999: Declaration of Thornton/Martin.
AJ	Opposition to EP 0456216, Attachment to Celltech Therapeutics' submissions of December 16, 1999: printouts from Protein Design Labs, Inc.'s website.
AK	Opposition to EP 0456216, Attachment to Celltech Therapeutics' submissions of December 16, 1999: Tables showing derivatization of the antibody domains referred to in Fig. 3 / line 4 and Fig. 4F of WO 88/09344.
AL	Opposition to EP 0456216, Attachment to Celltech Therapeutics' submissions of December 16, 1999: Schomburg, in <i>Advances in Protein Design</i> , Blöcker et al. (Eds.), 1989, pp. 45-56.
AM	Opposition to EP 0456216, Further Submissions of Genentech, Inc., December 17, 1999.
AN	Opposition to EP 0456216, Attachment to Genentech's submissions of December 17, 1999: Declaration of Verhoeven (including exhibits A, B and C).
AO	Opposition to EP 0456216, Attachment to Genentech's submissions of December 17, 1999: Declaration of Shak (including exhibits A, B and C).
AP	Opposition to EP 0456216, Attachment to Genentech's submissions of December 17, 1999: Declaration of Presta (including exhibits A and B).
AQ	Opposition to EP 0456216, Attachment to Genentech's submissions of December 17, 1999: Reply of Protein Design Labs, Inc. in European patent application 92903551.7.
AR	Opposition to EP 0456216, Attachment to Genentech's submissions of December 17, 1999: Letter of Dr. Seemann.
AS	Opposition to EP 0456216, Observations of Protein Design Labs, Inc., December 17, 1999.
AT	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of F. Vincenti (including exhibits 1 and 2).
AU	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of D. A. Scheinberg (including exhibits 1-4).

EXAMINER

Celia Burke, RLD

DATE CONSIDERED

4/28/00

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)		Attorney Docket No.: 11823-002630US	Application No.: 08/484,537
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: QUEEN ET AL.	
		Filing Date: June 7, 1995	Group: 1642
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)			
Page 2 of 2			
QB AV	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of M. Sung Co and Experimental report.		
QB AW	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of C. Nan Chang and Experimental report.		
QB AX	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of R. D. Kornberg.		
QB AY	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of M. Levitt.		
QB AZ	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of A. B. Edmundson.		
QB BA	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of R. Kirkman.		
QB BB	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of R. Junghans (including exhibits 1-6).		
QB BC	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of M. Vasquez.		
QB BD	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of D. Panka.		
QB BE	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of R. J. Poljak.		
QB BG	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of J. S. Huston.		
QB BH	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of C. Queen and experimental report.		
QB BJ	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of N. Tsurushita and experimental report.		
QB BN	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Declaration of W. Smith.		
QB BNS	Opposition to EP 0456216, Attachment to Observations of Protein Design Labs, Inc. submitted on December 17, 1999: Examiner's Reasons for Allowance for U.S. Patent No. 5,225,539.		
QB BL	Opposition to EP 0456216, Further Submissions of Schering Corp., February 11, 2000.		
QB BM	Opposition to EP 0456216, Further Submissions of Genentech, Inc., March 8, 2000.		
QB BN	Opposition to EP 0456216, Attachment to Genentech's submissions of March 8, 2000: Declaration of Foote.		
QB BN	Opposition to EP 0456216, Further Submissions of Genentech, Inc., March 13, 2000.		
QB BO	Opposition to EP 0456216, Further Submissions of Protein Design Labs, Inc., March 16, 2000.		
QB BO	Opposition to EP 0456216, Minutes of Oral Proceedings issued by the EPO, April 5, 2000.		
EXAMINER	DATE CONSIDERED 4/28/00		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

Attorney Docket No.
011823-002630Serial No.:
08/484,537LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

(Use several sheets if necessary)

Applicant: Queen

Filing Date: 6/7/95

Group: 1806

D33	Winter patent (Medical Research Council) See AV	See Foreign Patent Documents
D34	Diamanstein application (Bayer Aktiengesellschaft) See AW
D35	Verhoeven, BioEssays 8 (February/March 1988), 74-78	
D36	QR Riechmann, Nature 332 (March 1988), 323-327	
D37	QR Verhoeven, Science 239 (March 1988), 1534-1536	
D38	QR Panka, Proc. Natl. Acad. Sci. USA 85 (May 1988) 3080-3084	
D39	QR Davies, J. Biol. Chem., 263 (1988), 10541-10544	
D40	QR Cheetham, Prot. Eng., 2 (September 1988) 170-172	
D41	QR Matsumura, Nature, 334 (1988), 406-410	
D42	Huston application (Creative Biomolecules) See AX	See Foreign Patent Documents
D42'	Huston (Creative Biomolecules) WO88/09344 (December 1, 1988), Fig. 3	
D43	Huston application, See AV	See Foreign Patent Documents
D44	Comparison Chart for EP-A1 0 318 554 (Huston)	
D45	QR Hale, The Lancet 2 (December 17, 1988), 1394-1399	
D46	Bodmer application, (Celltech Limited), See AZ	See Foreign Patent Documents
D47	Hardman application, (Ciba-Geigy AG), See A1	
D48	Clark application (Medical Research Council), See A2	
D49	Queen application (Protein Design Labs, See A3	
D50	Hinton application (Becton Dickinson), See A4	
D51	Mezes application, (Dow Chemical) See A5	↓
D52	QR Queen, Proc. Natl. Acad. Sci., USA 86 (December 1989), 10029-10033	
D53	QR Chothia, Nature, 342, (1989), 877-883	
D54	QR Tramontano, J. Mol. Biol., 215 (1990), 175-182	
D55	Queen Application (Protein Design Labs) See AA	See US Patent Documents
D56	QR Co, Proc. Natl. Acad. Sci., USA 88 (1991), 2869-2873	
D57	QR Gorman, Proc. Natl. Acad. Sci., USA, 88 (1991), 4181-4185	
D58	QR Routledge, Eur. J. Immunol., 21 (1991), 2717-2725	
D59	QR Shearman, J. Immunol., 147 (1991), 4366-4373	
D60	QR Kettleborough, Protein Engineering, 4, (1991), 773-783	
D61	QR Tempest, Bio/Technology, 9, (1991), 266-271	

Julie (Reeves, PL)

B Jr 99